Neuren Pharmaceuticals(ASX:NEU)
Developing drug therapies forserious neurological disorders that emerge in early childhood &have no or limited treatment options
Highly successful US launchof DAYBUE™ (trofinetide) for Rett syndrome by partner Acadia
2023 net sales of US$177.2m;A$27m NEU royalties
1Q24 net sales US$75.9;A$11.6m royalties
2024 net sales guidance ofUS$370-420m; would earn NEU A$61-70m + A$77m sales milestone
Acadia advancingDAYBUE™ in Canada, Europe & Japan
NNZ-2591 in Phase 2 trialsfor four syndromes; 5x Rett market
All indications received FDAinvestigational new drug (IND) & orphan drug designation
Pitt Hopkins topline resultsexpected 2Q24, Angelman results expected 3Q24
Dec'23: PMS demonstratedsignificantly positive results, preparation underway for FDA end of Ph2 meeting
$243.1m cash as of 31 Mar'24
Market cap ~ $2.58B
- Forums
- ASX - By Stock
- NEU
- Neuren Media and Analyst Coverage
Neuren Media and Analyst Coverage, page-963
-
- There are more pages in this discussion • 255 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.01 |
Change
-0.200(0.99%) |
Mkt cap ! $2.557B |
Open | High | Low | Value | Volume |
$20.16 | $20.21 | $19.90 | $1.443M | 71.97K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 242 | $20.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.03 | 575 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 116 | 20.010 |
9 | 515 | 20.000 |
4 | 491 | 19.990 |
3 | 254 | 19.980 |
3 | 185 | 19.970 |
Price($) | Vol. | No. |
---|---|---|
20.020 | 15 | 1 |
20.030 | 179 | 4 |
20.040 | 404 | 10 |
20.050 | 582 | 9 |
20.060 | 693 | 9 |
Last trade - 11.32am 02/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online